entertainment -WSS

entertainment

author：knowledge 2025-08-26 07:42:20 - browse：63576

Two people run on the sugar-phosphate backbone of DNA while holding base pairs — in the lab coverage from STAT — Adobe

LONDON — Widespread genetic testing as well as the development of cutting-edge, customized genetic therapies have opened the door to treating many more inherited conditions than previously possible. A few recent cases, in which bespoke medicines were created for children with exceedingly rare mutations, have raised hopes for furthering the approach.

Now, researchers and government agencies in the U.K. are trying to figure out the nitty-gritty to replicate those early one-off successes for as many patients as possible — what sort of preclinical testing a tailor-made treatment needs to go through before being used, what regulatory thresholds each treatment needs to clear, and how to pay for these therapies.

“A lot of the barriers are no longer scientific — we can make these drugs,” said Matthew Wood, a professor of pediatrics at the University of Oxford. “It’s more about, can we make them at a cost that is reasonable enough? And can we get the regulators to reduce the barriers to doing this so that when a patient shows up, you can actually make a drug quickly enough to benefit that patient, rather than it costing huge amounts of money and taking two or three years to do it?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

WSS

Medicare Advantage isn’t working — for anyone

2023 STAT Wunderkinds: get to know the winners

NIH confirmation hearing shows politicization of research

Childhood vaccination ad campaign launches in the U.K.

Doctor of U.S. President Joe Biden says he is fit for duty

2023 STAT Wunderkinds: get to know the winners

entertainment

entertainment

explore

Sports medicine is finally prioritizing gender equality

STAT Madness 2024: Meet the contenders

What does generative AI mean for health care? We asked experts

Neuroscience renaissance leads to new crop of psychiatric drugs

Medicare proposal to cover medical devices draws a mixed reaction

Laying a path for careers in science

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Senate committee scrutinizes Medicare Advantage brokers

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

STAT Summit: GSK CEO on pharma giant's new direction

hotspot

CEOs share strategies for surviving biotech slump

Elisabeth Bik tackles the widespread issue of research misconduct

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Pharmacists can make shortage drugs, but at what cost?

Are embryos people? Reproductive medicine's future depends on the answer

FDA struggles to regulate food additives, sometimes for decades

hotspot

Wikipedia

focus

focus